The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer
- 1 August 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (15), 6660-6667
- https://doi.org/10.1158/0008-5472.can-04-3478
Abstract
Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein–specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR.Keywords
This publication has 28 references indexed in Scilit:
- Strategies for Inhibition of MDR1 Gene ExpressionMolecular Pharmacology, 2004
- Activation of theMDR1Upstream Promoter in Breast Carcinoma as a Surrogate for Metastatic InvasionClinical Cancer Research, 2004
- P-glycoprotein: from genomics to mechanismOncogene, 2003
- Multidrug resistance proteins and topoisomerase IIα expression in colon cancer: association with metastatic potentialPathology, 2003
- A New Quinoline Derivative MS‐209 Reverses Multidrug Resistance and Inhibits Multiorgan Metastases by P‐glycoprotein‐expressing Human Small Cell Lung Cancer CellsJapanese Journal of Cancer Research, 2001
- P‐glycoprotein stability is affected by serum deprivation and high cell density in multidrug‐resistant cellsJournal of Cellular Physiology, 1995
- Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-Glycoprotein in Breast CarcinomaJNCI Journal of the National Cancer Institute, 1991
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990
- Drug resistance in kht fibrosarcoma cell lines with different metastatic abilityInternational Journal of Cancer, 1989
- The mdrl gene, responsible for multidrug-resistance, codes for P-glycoproteinBiochemical and Biophysical Research Communications, 1986